Gene Logic Lowers Revenue Outlook for 2003 | GenomeWeb

NEW YORK, Sept. 23 (GenomeWeb News) - Gene Logic said that it has lowered its revenue guidance for 2003 to a range of $72 million to $76 million, on a pro forma basis.

In late July, Gene Logic had said it was expecting its pro forma revenues for the year to be between $80 million to $84 million.

Gene Logic said that the pro forma results assume that the company's April 1 acquisition of TherImmune took place on January 1. Actual revenues for the year are expected to be in the range of $65 million to $69 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.